NASDAQ:NOVN
Delisted
Novan, Inc. Stock News
$0.0941
+0 (+0%)
At Close: Nov 20, 2023
Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA
05:15am, Friday, 17'th Jun 2022 GlobeNewswire Inc.
Basel, June 17, 2022 — Sandoz, a global leader in generic and biosimilar medicines, today announced that the European Medicines Agency (EMA) has accepted the application for high concentration form
New research reveals the critical actions needed to ensure COVID-19-driven surge in virtual health and care drives health access and equity
05:15am, Thursday, 16'th Jun 2022 GlobeNewswire Inc.
Basel, June 16, 2022 — Many unnecessary restrictions on virtual health and care were swept away by the pandemic, and most people have embraced this new world of virtual care, according to a new repo
Novan Announces Closing of Approximately $15.0 Million Registered Direct Offering Priced At-the-Market
08:05pm, Monday, 13'th Jun 2022 GlobeNewswire Inc.
DURHAM, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the closing of the Company’s previously announced registered direct o
Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL
09:30am, Sunday, 12'th Jun 2022 GlobeNewswire Inc.
Basel, June 12, 2022 — Novartis today announced long-term five-year follow-up results from the ELIANA pivotal clinical trial of Kymriah® (tisagenlecleucel), the first-ever approved CAR-T cell thera
Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL
09:30am, Sunday, 12'th Jun 2022 GlobeNewswire Inc.
Basel, June 12, 2022 — Novartis today announced long-term results from the ELIANA pivotal clinical trial of Kymriah® (tisagenlecleucel), the first-ever approved CAR-T cell therapy, in children and
Novan Announces Approximately $15.0 Million Registered Direct Offering Priced At-the-Market
12:30pm, Thursday, 09'th Jun 2022 GlobeNewswire Inc.
DURHAM, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it has entered into a definitive agreement with an institutional invest
Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial
02:45pm, Tuesday, 07'th Jun 2022 GlobeNewswire Inc.
Basel, June 7, 2022 — Novartis today announced longer-term follow-up data from the Phase III ASCEMBL trial for patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phas
Is WisdomTree International High Dividend ETF (DTH) a Strong ETF Right Now?
10:20am, Monday, 06'th Jun 2022 Zacks Investment Research
Smart Beta ETF report for DTH
Sandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030
05:15am, Tuesday, 31'st May 2022 GlobeNewswire Inc.
Basel, May 31, 2022 – Sandoz, a global leader in generic and biosimilar medicines, today announced the launch of a new global initiative called ‘Act4Biosimilars’ to help address health inequity
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
10:58pm, Friday, 27'th May 2022 GlobeNewswire Inc.
Basel, May 28, 2022 — Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah® (tisagenlecleucel) for the treatment of adult patients with re
Sandoz appoints new Board representative to global AMR Industry Alliance
07:00am, Friday, 27'th May 2022 GlobeNewswire Inc.
Basel, May 27, 2020 — Sandoz is pleased to announce the appointment of Dr. Boumediene Soufi, global head of the Sandoz Antimicrobial Resistance (AMR) program, as its new representative to the Board
Novartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions
12:34pm, Friday, 20'th May 2022 GlobeNewswire Inc.
Basel, May 20, 2022 — Novartis today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx® (secukin
Novan to Present Berdazimer Gel, 10.3% (SB206) Clinical Data at Annual Meeting of the Society for Investigative Dermatology
01:05pm, Thursday, 19'th May 2022 GlobeNewswire Inc.
– Based on clinical data from previously completed B-SIMPLE4 pivotal Phase 3 clinical study, berdazimer gel, 10.3% (SB206) can shorten the duration of molluscum infection and increase the chance of
Novan to Present Berdazimer Gel, 10.3% (SB206) Clinical Data at Annual Meeting of the Society for Investigative Dermatology
09:05am, Thursday, 19'th May 2022
– Based on clinical data from previously completed B-SIMPLE4 pivotal Phase 3 clinical study, berdazimer gel, 10.3% (SB206) can shorten the duration of molluscum infection and increase the chance of
Novan, Inc. (NOVN) CEO Paula Brown Stafford on Q1 2022 Results - Earnings Call Transcript
11:21am, Monday, 16'th May 2022
Novan, Inc. (NASDAQ:NOVN ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Paula Brown Stafford - Chairman, President and Chief Executive Officer John Donofrio - Chief Op
